Achieve life sciences strengthens leadership with appointment of dr. mark rubinstein, nicotine dependence expert, as new head of medical affairs

Seattle and vancouver, british columbia, oct. 01, 2024 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, is pleased to announce the appointment of dr. mark l. rubinstein as its new head of medical affairs. dr. rubinstein brings more than two decades of experience in clinical medicine, scientific research, and medical affairs leadership, with a strong focus on preventative medicine and nicotine cessation.
ACHV Ratings Summary
ACHV Quant Ranking